U.K. Provides £50 Million Extra For Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Extra funds made available in the U.K. for anti-cancers turned down by NICE, with a £200 million fund to be set up next year.
You may also be interested in...
Pfizer’s Bosulif Too Expensive And Lacks Data, Says NICE
NICE has rejected Bosulif for leukemia principally on cost grounds, but also due to a lack of comprehensive long-term data, which is also being sought by the EMA.
Xolair’s Price Discount For NICE Is Ominous Sign For Older Products
Novartis essentially makes volume trade-off in the most recent NICE assessment, adding a claim for ages 6-11 but offering pricing concessions as well; if the firm’s experience is any indication, even older products that come under NICE’s cost-effectiveness scrutiny will need discounts and additional data to stay in the authority’s good graces.
End-Of-Life-Considerations Fail To Save Lilly’s Alimta For NSCLC At NICE
Britain’s NICE has rejected Eli Lilly’s Alimta for non-small-cell lung cancer, citing cost-effectiveness issues. But the US drug maker still has options to get the drug approved by the pricing watchdog.